Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
M.D. Anderson Cancer Center
With
National Cancer Institute (NCI)
PRIMARY OBJECTIVES:
I. To assess the value and/or limitations of using orally supplemented arginine (L-arginine) to improve renal function associated with the use of anti-angiogenic therapies that target vascular endothelial growth factor (VEGF).
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive arginine orally (PO) four times daily (QID). Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.
GROUP II: Patience receive placebo PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.
After completion of study treatment patients are followed up within 1 month.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
On or enrolled for anti-VEGF therapy
Systolic Blood Pressure \>= 140 mm Hg
Diastolic Blood Pressure \>= 90 mm Hg
Proteinuria \>= 500 mg/day or worsening glomerular filtration rate (GFR) (\> 0.3 mg/dl in 48 hours \[hrs.\] or \> 50% decline from baseline creatinine in 1 week)
You may not be if
Allergy to L-arginine
Systolic Blood Pressure \< 140 mm Hg
Diastolic Blood Pressure \< 90 mm Hg
Proteinuria \< 500 mg/day
Continuous tube feeds (since the medication will be given in-between meals)
